Agenus Initiates Phase 3 Trial for Immunotherapy in Difficult-to-Treat Colorectal Cancer
Event summary
- Agenus initiated the global Phase 3 BATTMAN (CO.33) trial on April 1, 2026.
- The trial will evaluate the combination of botensilimab (BOT) and balstilimab (BAL) versus best supportive care.
- The study aims to enroll approximately 830 patients across Canada, France, Australia, and New Zealand.
- The trial focuses on patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC).
The big picture
The BATTMAN trial represents a significant effort to expand the applicability of immunotherapy to a patient population—MSS/pMMR mCRC—that has historically been unresponsive. This trial's outcome could reshape the treatment landscape for a substantial portion of colorectal cancer patients, potentially unlocking a broader market for Agenus' immunotherapy platform. The rapid enrollment suggests a significant unmet need and a willingness among clinicians to explore novel approaches, but also highlights the competitive pressure in the immuno-oncology space.
What we're watching
- Clinical Efficacy
- The trial's success hinges on demonstrating a statistically significant survival benefit for the BOT+BAL combination compared to standard care, a challenging feat given the historically resistant nature of MSS/pMMR mCRC.
- Enrollment Speed
- Rapid enrollment, attributed to investigator enthusiasm, could indicate strong physician buy-in and patient willingness, but also raises questions about potential recruitment biases or accelerated site activation.
- Regulatory Pathway
- The trial's designation as 'registrational-enabling' suggests Agenus intends to seek accelerated approval, which will depend heavily on the trial’s design and the strength of the data generated.
Related topics